மருந்துகள் ஆரீட News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from மருந்துகள் ஆரீட. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In மருந்துகள் ஆரீட Today - Breaking & Trending Today

Azure Health Technology Limited (NSX:VTL) Appointment of cGMP Manufacturer


Azure Health Technology Limited (NSX:VTL) Appointment of cGMP Manufacturer
  
Appointment of cGMP ManufacturerSydney, June 7, 2021 AEST (ABN Newswire) - Azure Health Technology Limited trading as VGI Health Technology (
NSX:VTL) is pleased to announce that an additional current Good Manufacturing Practice (cGMP) manufacturer has been appointed in the US.
VTL has executed a Manufacturing and Supply Agreement with Altipure LLC, a clinical partner of Muscle Feast, LLC in Ohio, USA, after the completion of a pilot manufacturing project which produced clinical study drugs for VTL s two Phase II clinical studies.
In this pilot manufacturing run which has recently been completed, 60,000 doses of active clinical study drug and 60,000 doses of placebo were manufactured and are expected to arrive in Australia in July 2021. ....

United States , New South Wales , Azure Health Technology , Azure Health Technology Limited , Health Technology , Muscle Feast , Health Technology Limited , Good Manufacturing Practice , Supply Agreement , Alcoholic Fatty Liver Disease , Non Alcholic Steatoheptatitis , Pancreatic Cancer , Delayed Onset Muscle Soreness , Managing Director , Clinical Trials , Drugs Otc , Nsx Vtl , ஒன்றுபட்டது மாநிலங்களில் , புதியது தெற்கு வேல்ஸ் , நீலமான ஆரோக்கியம் தொழில்நுட்பம் , நீலமான ஆரோக்கியம் தொழில்நுட்பம் வரையறுக்கப்பட்டவை , ஆரோக்கியம் தொழில்நுட்பம் , ஆரோக்கியம் தொழில்நுட்பம் வரையறுக்கப்பட்டவை , நல்ல உற்பத்தி ப்ர்யாக்டீஸ் , ஆல்கஹால் கொழுப்பு கல்லீரல் நோய் , கணையம் புற்றுநோய் ,

Anatara Lifesciences Ltd (ASX:ANR) Q3 FY21 Activities Report - ABN Newswire (@ABN_Newswire)


Anatara Lifesciences Ltd (ASX:ANR) Q3 FY21 Activities Report
  
Q3 FY21 Activities ReportMelbourne, April 27, 2021 AEST (ABN Newswire) - Anatara Lifesciences (
ASX:ANR), a developer of non-antibiotic oral solutions for gastrointestinal diseases in animals and humans, is pleased to provide this activities report for the quarter ending 31 March 2021, along with the Company s Appendix 4C cash flow report.
Commenting on the quarter, CEO Steve Lydeamore said, Anatara is pleased to have successfully progressed two key milestones during the period - a successful trial for Anatara s proprietary enriched formulation for poultry in water, and ethics approval to start the human IBS trial.
Anatara now has approval to commence two separate human trials for its Gastrointestinal Re-Programming complementary medicine (GaRP), and there appears to be a wider appreciation of the Company s human health initiatives and the potential to improve overall human wellbeing with ....

April Anatara , Anatara Ga , Steve Lydeamore , Anatara Lifesciences , Human Research Ethics Committee , Anatara Lifesciences Ltd , Company Appendix , Gastrointestinal Re Programming , February Anatara , Psychological Functioning Trial , Escherichia Coli , Drugs Otc , Health Pharm General , Asx Anr , மனிதன் ஆராய்ச்சி நெறிமுறைகள் குழு , நிறுவனம் பின் இணைப்பு , இரைப்பை குடல் ரே ப்ரோக்ராமிஂக் , மருந்துகள் ஆரீட , ஆரோக்கியம் பார்ம் ஜநரல் , அஸ்ஸ் ஆர் ,